Article

Targeted dendrimer chemotherapy in an animal model for head and neck squamous cell carcinoma.

Michigan Nanotechnology Institute for Medicine and Biological Sciences, and Department of Oral and Maxillofacial Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons (Impact Factor: 1.58). 06/2011; 69(9):2452-9. DOI: 10.1016/j.joms.2010.12.041
Source: PubMed

ABSTRACT Nanoparticle drug delivery offers a potential solution in the treatment of cancer. Using a heterotopic tumor model for head and neck squamous cell carcinoma (HNSCC), tumors of variable folate binding protein-alpha (FBP-α) have been treated to delineate receptor necessity as well as efficacy and toxicity of folate targeted chemotherapy.
University of Michigan Squamous Cell Carcinoma (UM-SCC) and American Type Culture Collection (ATCC) cell lines were screened using quantitative real-time polymerase chain reaction for FBP-α expression. Acetylated generation 5 dendrimers conjugated to the targeting moiety folic acid and the therapeutic moiety methotrexate were fabricated and administered to severe combined immunodeficiency (SCID) CB-17 mice inoculated with UM-SCC-1, UM-SCC-17B, and UM-SCC-22B cancer cells. Mice were injected with targeted therapy, free methotrexate, or saline control and monitored for drug efficacy and toxicity.
Targeted therapy was effective relative to receptor level expression. Targeted therapy could be delivered in molar doses 3 times that of free drug. The treatment of a high folate expression tumor cell population was noted to have increased efficacy over saline (P < .01) and free methotrexate (P = .03) as well as decreased systemic toxicity.
This report represents the first translation of dendrimer-based chemotherapy to HNSCC and underscores its effectiveness as an antitumor agent in human cancer cell lines with lower levels of FBP-α than the in vitro and in vivo models previously reported.

1 Bookmark
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Head-and-neck cancer is a major form of the disease worldwide. Treatment consists of surgery, radiation therapy and chemotherapy, but these have not resulted in improved survival rates over the past few decades. Versatile nanoparticles, with selective tumor targeting, are considered to have the potential to improve these poor outcomes. Application of nanoparticle-based targeted therapeutics has extended into many areas, including gene silencing, chemotherapeutic drug delivery, radiosensitization, photothermal therapy, and has shown much promise. In this review, we discuss recent advances in the field of nanoparticle-mediated targeted therapeutics for head-and-neck cancer, with an emphasis on the description of targeting points, including future perspectives.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyamidoamine (PAMAM) dendrimers of the second generation (G2) are branched polymers containing 16 surface amino groups that allow them to be used as universal carriers on creating systems for drug delivery. G2 labeled with fluorescein isothiocyanate (FITC) efficiently bound with the surface of tumor cells at 4°C and was absorbed by the cells at 37°C. The covalent binding to G2-FITC of a vector protein, a recombinant fragment of the human alpha-fetoprotein receptor-binding domain (rAFP3D), increased the binding and endocytosis efficiency more than threefold. Covalent conjugates of G2 with doxorubicin (Dox) obtained by acid-labile linking of cis-aconitic anhydride (CAA) without the vector protein (G2-Dox) and with the vector protein rAFP3D (rAFP3D-G2-Dox) were accumulated by the tumor cells with high efficiency. However, a selective effect was observed only in rAFP3D-G2-Dox, which also demonstrated high cytotoxic activity against the human ovarian adenocarcinoma SKOV3 cells and low cytotoxicity against human peripheral blood lymphocytes. Based on these results, rAFP3D-G2 conjugate is promising for selective delivery of antitumor drugs.
    Biochemistry (Moscow) 08/2013; 78(8):884-894. DOI:10.1134/S000629791308004X · 1.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanotechnology, a separate field of knowledge since 1980s, involves utilization of nanomaterials not only in electronics and catalysis, but also in biomedical research including drug delivery, bioimaging, biomedical-diagnostics and tissue engineering. Multidisciplinary of this science has led to the development of different areas of technology and might contribute to innovations that will, as a final consequence, help humanity. Dendrimers are large and complex molecules that are characterized by well-defined nanoscale architecture, monodispersity and structural versatility. These highly interesting polymers consist of three elements: core, branches and peripheral groups. There is a wide variety of potential applications of dendritic polymers. One of the most promising is utilization of polyamidoamine (PAMAM) dendrimers as drug delivery devices. Among pharmaceuticals that have been connected with different types of dendrimers are nonsteroidal anti-inflammatory drugs (NSAIDs), anticancer drugs and other. Dendrimers application as drug carriers improves pharmacokinetic properties of drug particles, decreases drugs' side effects and, by possibility of surface modification with different ligands, enables to target specific tissues and tumor cells. Dendrimers might be also utilized as devices for delivery of genetic material and contrast agents for magnetic resonance imaging (MRI).
    Nano brief reports and reviews 05/2012; 06(06). DOI:10.1142/S1793292011002871 · 1.26 Impact Factor

Full-text (2 Sources)

Download
128 Downloads
Available from
May 22, 2014